Sensitizing tumor cells to radiotherapy

Head and neck squamous cell carcinoma (HNSCC) is the fifth most common cancer worldwide. Tumor resistance to radio- and/or chemotherapy remains a significant clinical problem.

A team of researchers led by Nils Cordes, at Dresden University of Technology, Germany, has now identified a way to enhance the sensitivity of human HNSCC cell lines to radiation such that their growth is delayed in xenografted mice.

In the study, Cordes and colleagues determined that a beta-1 integrin/FAK/cortactin signaling pathway is crucial for HNSCC resistance to radiotherapy. Inhibiting beta-1 integrin sensitized HNSCC cells to radiotherapy and delayed in xenografted mice. Thus, Cordes and colleagues suggest that targeting beta-1 integrin could be used in combination with radiotherapy and radiochemotherapy to increase the survival of patients with HNSCC.

More information: Beta-1 integrin/FAK/cortactin signaling is essential for human head and neck cancer resistance to radiotherapy, Journal of Clinical Investigation.

add to favorites email to friend print save as pdf

Related Stories

Blocking beta1-integrin to treat cancer

Jun 06, 2007

Targeting the function of a protein known as beta1-integrin might represent a novel approach to cancer treatment, according to a paper published online in The EMBO Journal this week. Blocking the action of this protein could ...

PXR: A stepping stone from environmental chemical to cancer?

Jul 11, 2011

Several chemicals that can accumulate to high levels in our body (for example BPA and some pesticides) have been recently linked to an increased risk of cancer and/or impaired responsiveness to anticancer drugs. A team of ...

Recommended for you

Survival hope for melanoma patients thanks to new vaccine

4 hours ago

(Medical Xpress)—University of Adelaide researchers have discovered that a new trial vaccine offers the most promising treatment to date for melanoma that has spread, with increased patient survival rates and improved ability ...

New clinical trial launched for advance lung cancer

7 hours ago

Cancer Research UK is partnering with pharmaceutical companies AstraZeneca and Pfizer to create a pioneering clinical trial for patients with advanced lung cancer – marking a new era of research into personalised medicines ...

User comments